Nirav Shah, MD, on the Potential of Dual-Targeted CAR-T in Chronic Lymphocytic Leukemia
The associate professor of medicine at Medical College of Wisconsin discussed clinical results from patients with CLL and Richter’s transformation treated with CD19/CD20-targeted CAR-T LV20.19.
Nirav Shah, MD, on New Data on Zamto-cel in DLBCL, Mantle Cell Lymphoma
The associate professor of medicine at Medical College of Wisconsin discussed trials assessing the dual, CD19/CD20-targeting CAR T therapy.
Nirav N. Shah, MD, on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies
The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.
Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma
Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.
Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma
Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.
Dr. Shah on Dosing Tandem Receptor CAR T-Cell Therapy in B-Cell Malignancies
Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.
Dr. Shah on Differences Between Anti-CD19 CAR T-Cell Therapies
Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.
Dr. Shah Discusses Ongoing Research With CAR T-Cell Therapy
Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.